133 related articles for article (PubMed ID: 31581912)
41. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors.
Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z
Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625
[TBL] [Abstract][Full Text] [Related]
42. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.
Friberg A; Vigil D; Zhao B; Daniels RN; Burke JP; Garcia-Barrantes PM; Camper D; Chauder BA; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2013 Jan; 56(1):15-30. PubMed ID: 23244564
[TBL] [Abstract][Full Text] [Related]
43. Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.
Cook SJ; Stuart K; Gilley R; Sale MJ
FEBS J; 2017 Dec; 284(24):4177-4195. PubMed ID: 28548464
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
45. Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode.
Hedir S; De Giorgi M; Fogha J; De Pascale M; Weiswald LB; Brotin E; Marekha B; Denoyelle C; Denis C; Suzanne P; Gautier F; Juin P; Ligat L; Lopez F; Carlier L; Legay R; Bureau R; Rault S; Poulain L; Oliveira Santos JS; Voisin-Chiret AS
Eur J Med Chem; 2018 Nov; 159():357-380. PubMed ID: 30308410
[TBL] [Abstract][Full Text] [Related]
46. Regulation of Apoptosis by the Bcl-2 Family of Proteins: Field on a Brink.
Ladokhin AS
Cells; 2020 Sep; 9(9):. PubMed ID: 32961920
[TBL] [Abstract][Full Text] [Related]
47. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
48. Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa.
Wang X; Gu Z; Li G; Zhang S; Cao Z; Yang Z; Liu G
Oncol Rep; 2014 Aug; 32(2):716-22. PubMed ID: 24891300
[TBL] [Abstract][Full Text] [Related]
49. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
50. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
Wei J; Kitada S; Stebbins JL; Placzek W; Zhai D; Wu B; Rega MF; Zhang Z; Cellitti J; Yang L; Dahl R; Reed JC; Pellecchia M
J Med Chem; 2010 Nov; 53(22):8000-11. PubMed ID: 21033669
[TBL] [Abstract][Full Text] [Related]
52. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
[TBL] [Abstract][Full Text] [Related]
54. Forecast: rough seas for leukemia.
Hockenbery DM
Cancer Discov; 2014 Mar; 4(3):278-9. PubMed ID: 24596202
[TBL] [Abstract][Full Text] [Related]
55. Discovery and structure-activity relationship studies of novel Bcl-2/Mcl-1 dual inhibitors with indole scaffold.
Zhang Z; Hou L; Bai L; Pei J; Zhao S; Luan S; Liu D; Huang M; Zhao L
Bioorg Chem; 2022 Aug; 125():105845. PubMed ID: 35512494
[TBL] [Abstract][Full Text] [Related]
56. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
[TBL] [Abstract][Full Text] [Related]
58. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.
Sun YL; Jiang WQ; Luo QY; Yang DJ; Cai YC; Huang HQ; Sun J
BMC Cancer; 2019 Dec; 20(1):1. PubMed ID: 31892356
[TBL] [Abstract][Full Text] [Related]
59. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
[TBL] [Abstract][Full Text] [Related]
60. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
